rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2001-12-28
|
pubmed:abstractText |
Therapy for prostate cancer in the PC3 tumor-nude mouse model with 90yttrium-(90Y)-DOTA-peptide-ChL6 (5.55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested for synergy with 90Y-DOTA-peptide-ChL6.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0270-4137
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
27-37
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11757033-Animals,
pubmed-meshheading:11757033-Combined Modality Therapy,
pubmed-meshheading:11757033-Heterocyclic Compounds,
pubmed-meshheading:11757033-Humans,
pubmed-meshheading:11757033-Male,
pubmed-meshheading:11757033-Mice,
pubmed-meshheading:11757033-Mice, Nude,
pubmed-meshheading:11757033-Neoplasm Transplantation,
pubmed-meshheading:11757033-Oligopeptides,
pubmed-meshheading:11757033-Paclitaxel,
pubmed-meshheading:11757033-Prostatic Neoplasms,
pubmed-meshheading:11757033-Radiation-Sensitizing Agents,
pubmed-meshheading:11757033-Radioimmunotherapy,
pubmed-meshheading:11757033-Taxoids,
pubmed-meshheading:11757033-Transplantation, Heterologous,
pubmed-meshheading:11757033-Yttrium
|
pubmed:year |
2002
|
pubmed:articleTitle |
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
|
pubmed:affiliation |
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis & Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA. rtodonnell@ucdavis.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|